Regeneron Pharmaceuticals, Inc. (REGN) company profile
Close on Nov 13, 2026Market cap $98.84BP/E 21.1Yield –
About Regeneron Pharmaceuticals
Pharmaceutical Preparations, SIC 2834
Regeneron Pharmaceuticals, Inc. is a biotechnology enterprise that discovers, invents, develops, manufactures, and commercializes medicines for serious medical conditions. Its commercial portfolio and clinical pipeline address eye diseases, allergic and inflammatory conditions, oncology, cardiovascular and metabolic disorders, neurological conditions, hematologic conditions, infectious diseases, and rare disorders. Key commercial medicines include EYLEA and EYLEA HD for retinal diseases, Dupixent for inflammatory indications, Libtayo for oncology, and Kevzara for inflammatory arthritis. The company serves patients and medical professionals requiring specialized prescription treatments.
The company markets and distributes its therapies internationally, with product approvals spanning the United States, the European Union, Japan, and other territories. Regeneron supplies commercial medicines both independently and through commercial partnerships across the United States and global markets. The provided text does not state its headquarters location or founding details.
Summary of the business section of Regeneron Pharmaceuticals's latest annual report, written by StockData.
Company profile
Company
- Legal name
- Regeneron Pharmaceuticals, Inc.
- Founded
- 1988
- Headquarters
- Tarrytown, NY
- Address
- 777 Old Saw Mill River Road 10591
- Phone
- (914) 847-7000
- Website
- www.regeneron.com
- Employees
- 15,410, Dec 31, 2025
- Industry
- Pharmaceutical Preparations
- Incorporated in
- New York
- Fiscal year ends
- December 31
- Auditor
- PricewaterhouseCoopers LLP, Florham Park, New Jersey
Stock & identifiers
- Ticker
- REGN
- Exchange
- Nasdaq
- IPO date
- Apr 2, 1991
- Shares outstanding
- 103M, Oct 22, 2026
- Public float
- $54.80B, Jun 30, 2025
- Filer category
- Large accelerated filer
- SEC CIK
- 872589
- CUSIP
- 75886F107
- ISIN
- US75886F1075
- FIGI
- BBG000C734W3
- Share class FIGI
- BBG001S6PX49
- LEI
- 549300RCBFWIRX3HYQ56
- EIN
- 13-3444607
Executives and directors
Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years
| Name | Position | Shares owned |
|---|---|---|
| George Yancopoulos | Bd. Co-Chair, President & CSO, Director | 1,125,945 |
| Leonard S. Schleifer | Bd. Co-Chair, President & CEO, Director | 2,442,116 |
| Jason Pitofsky | SVP Controller | 4,320 |
| Andrew J. Murphy | Co-Chief Scientific Officer | 51,193 |
| Joseph J. Larosa | EVP General Counsel and Secret | 44,726 |
| Christopher R. Fenimore | EVP Finance CFO | 25,249 |
| Marion McCourt | EVP Commercial | 11,090 |
| Plew Daniel P. Van | EVP & General Mgr, Industrial | 35,178 |
| Neil Stahl | EVP Research and Development | 59,283 |
| Huda Y. Zoghbi | Director | 1,703 |
| Christine A. Poon | Director | 5,219 |
| George L. Sing | Director | 27,297 |
| Kathryn Guarini | Director | 603 |
| Michael S. Brown | Director | 12,865 |
| Arthur F. Ryan | Director | 17,303 |
| Bonnie L. Bassler | Director | 3,203 |
| N. Anthony Coles | Director | 1,714 |
| David P. Schenkein | Director | 603 |
| Craig B. Thompson | Director | 775 |
| Joseph L. Goldstein | Director | 6,703 |
CEO pay and shareholder return
Pay versus performance table from the proxy statement
| Fiscal year | CEO total pay | CEO pay actually paid | Other executives (avg) | Value of $100 invested | Peer group |
|---|---|---|---|---|---|
| FY2025 | $7.28M | $38.95M | $7.73M | $160 | $201 |
| FY2024 | $6.82M | -$37.70M | $6.07M | $147 | $156 |
| FY2023 | $8.18M | $141.07M | $6.71M | $182 | $144 |
| FY2022 | $7.00M | $98.79M | $8.06M | $149 | $139 |
| FY2021 | $6.47M | $123.74M | $7.55M | $131 | $124 |
| FY2020 | $135.35M | $153.04M | $40.06M | $129 | $111 |
“Actually paid” adjusts reported pay for changes in the value of equity awards. Shareholder return assumes $100 invested at the start of the measurement period, as disclosed by the company.
Executive compensation, fiscal 2025
Summary compensation table from the latest proxy statement
| Executive | Salary | Bonus | Stock awards | Option awards | Incentive pay | Other | Total | vs. prior year |
|---|---|---|---|---|---|---|---|---|
| Leonard S. Schleifer, M.D., Ph.D. Board co-Chair, President and Chief Executive Officer | $1.98M | – | – | – | $3.68M | $1.62M | $7.28M | +7% |
| George D. Yancopoulos, M.D., Ph.D. Board co-Chair, President and Chief Scientific Officer | $1.98M | – | – | – | $3.68M | $1.29M | $6.95M | +2% |
| Christopher Fenimore Executive Vice President, Finance and Chief Financial Officer | $725.00K | – | $2.20M | $3.30M | $721.01K | $39.62K | $6.99M | +11% |
| Daniel P. Van Plew Executive Vice President and General Manager, Industrial Operations and Product Supply | $983.38K | – | $2.70M | $4.05M | $965.19K | $82.21K | $8.78M | +1% |
| Andrew J. Murphy, Ph.D. Executive Vice President, Co-Chief Scientific Officer | $819.67K | – | $2.70M | $4.05M | $815.16K | $92.80K | $8.48M | +1% |
| Joseph J. LaRosa Executive Vice President, General Counsel and Secretary | $916.06K | $1.00M | $1.80M | $2.70M | $911.02K | $132.74K | $7.46M | – |
Stock and option awards are grant-date fair values, not realized pay. “Other” includes pension value changes and all other compensation. Source proxy statement.
Employees
Headcount reported in annual reports
“As of December 31, 2025, we had 15,410 full-time employees, consisting of 11,961 employed in the United States, 2,149 employed in Ireland, and 1,300 employed in other countries (primarily in the United Kingdom, Japan, and Germany).”
Corporate history
Events identified from SEC filings
| Date | Event | Details |
|---|---|---|
| Aug 25, 2023 | Tender offer | Third-party tender offer for the company's shares |
| May 2, 2022 | Tender offer | Third-party tender offer for the company's shares |
| Oct 20, 2006 | Deregistration | Termination of SEC registration (Form 15) |
See a number that looks wrong?